These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17419693)

  • 21. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
    Bloor AJ; Thomson K; Chowdhry N; Verfuerth S; Ings SJ; Chakraverty R; Linch DC; Goldstone AH; Peggs KS; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):50-8. PubMed ID: 18158961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease.
    Kim SY; Lee DG; Kim MS; Kim HJ; Lee S; Min CK
    Am J Hematol; 2008 Oct; 83(10):784-8. PubMed ID: 18661492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment of refractory joint contractures caused by sclerodermatous graft versus host disease.
    Kim JB; Liakopoulou E; Watson JS
    J Plast Reconstr Aesthet Surg; 2008 Oct; 61(10):1235-8. PubMed ID: 17509955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.
    Lawler M; McCann SR; Marsh JC; Ljungman P; Hows J; Vandenberghe E; O'Riordan J; Locasciulli A; Socié G; Kelly A; Schrezenmeier H; Marin P; Tichelli A; Passweg JR; Dickenson A; Ryan J; Bacigalupo A;
    Br J Haematol; 2009 Mar; 144(6):933-45. PubMed ID: 19183198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
    van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells.
    Trzonkowski P; Bieniaszewska M; Juścińska J; Dobyszuk A; Krzystyniak A; Marek N; Myśliwska J; Hellmann A
    Clin Immunol; 2009 Oct; 133(1):22-6. PubMed ID: 19559653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic stem cell transplantation after reduced-intensity conditioning for acute myeloid leukaemia: impact of chronic graft-versus-host disease.
    Valcárcel D; Martino R; Piñana JL; Sierra J
    Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S35-7. PubMed ID: 19561412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation.
    Iori AP; Torelli GF; De Propris MS; Milano F; Pupella S; Gozzer M; Mancini F; Milani ML; Intoppa S; Cerretti R; Lucarelli B; Valle V; Malandruccolo L; Iannella E; Arleo E; Guarini A; Foà R
    Transplantation; 2008 Feb; 85(3):386-90. PubMed ID: 18322430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Annular plaques: An unusual manifestation of graft-versus-host disease.
    Alexander LJ; Paravar T; Duvic M; Prieto V; Hymes SR
    Dermatol Online J; 2012 Jun; 18(6):4. PubMed ID: 22747928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sclerodermiform chronic graft-versus-host disease after allogenic peripheral blood stem-cell transplantation].
    Neid T; Danz B; Eismann R; Bramsiepe I; Wohlrab J; Marsch WC; Fiedler E
    Dtsch Med Wochenschr; 2009 May; 134(21):1106-9. PubMed ID: 19437374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.
    Magro L; Catteau B; Coiteux V; Bruno B; Jouet JP; Yakoub-Agha I
    Bone Marrow Transplant; 2008 Dec; 42(11):757-60. PubMed ID: 18762765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
    Godder KT; Henslee-Downey PJ; Mehta J; Park BS; Chiang KY; Abhyankar S; Lamb LS
    Bone Marrow Transplant; 2007 Jun; 39(12):751-7. PubMed ID: 17450185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-transplant infections: single center experience from the developing world.
    Ullah K; Raza S; Ahmed P; Chaudhry QU; Satti TM; Ahmed S; Mirza SH; Akhtar F; Kamal K; Akhtar FM
    Int J Infect Dis; 2008 Mar; 12(2):203-14. PubMed ID: 17920999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease.
    Auletta JJ; Cooke KR
    Curr Opin Pediatr; 2009 Feb; 21(1):30-8. PubMed ID: 19242239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.